Summary & Overview
HCPCS Q5116: Trastuzumab-qyyp (Trazimera) Injection, 10 mg
HCPCS Level II code Q5116 designates a 10 mg unit of trastuzumab-qyyp (Trazimera), a biosimilar formulation of trastuzumab used in oncology. This code represents a biologic injectable therapy commonly administered for HER2-positive cancers and is relevant for facility and clinician billing where biosimilar substitution, dosing by weight, and infusion services are common. Nationally, accurate coding of biosimilars like trastuzumab-qyyp affects claim processing, inventory tracking, and payer coverage determinations for high-cost oncology treatments.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage landscapes, common billing and service-line contexts, and clinical context for use of trastuzumab biosimilars. The publication summarizes benchmarks and policy considerations relevant to reimbursement and utilization management for biosimilar monoclonal antibodies, highlights site-of-service implications for infusion administration, and outlines areas where coding clarity can impact claim adjudication. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q5116 describes an injection of trastuzumab-qyyp (Trazimera), a biosimilar to trastuzumab, provided in a 10 mg unit. The service reflected by this code is administration of a monoclonal antibody therapy used in oncologic care for conditions where trastuzumab is indicated.
Service type: Intravenous biologic injection/infusion for chemotherapy or targeted therapy.
Typical site of service: Hospital outpatient infusion centers, physician office infusion suites, and ambulatory infusion clinics.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with HER2-positive breast cancer receiving outpatient intravenous oncology therapy. The patient presents to an infusion center for a planned administration of trastuzumab biosimilar Q5116 (trazimera) as part of adjuvant therapy, neoadjuvant therapy, or for metastatic disease management. The clinical workflow includes verification of orders and chemotherapy plan by the oncology clinician and pharmacist, pre-infusion assessment (vital signs, weight, review of allergies and prior infusion reactions), preparation of the appropriate dose in pharmacy using aseptic technique, and nurse verification of patient identity and consent. The infusion nurse administers Q5116 via IV infusion or IV push per institutional protocol, monitors for infusion-related or cardiotoxic adverse events during and after administration, documents lot number and units billed, and coordinates scheduling of follow-up doses. Billing uses the HCPCS Level II code Q5116 reported with applicable modifiers reflecting payer requirements, and accompanying diagnosis codes that indicate HER2-positive breast cancer or related malignant neoplasm.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered |